News
IDYA
31.49
-3.74%
-1.23
IDEAYA Advances Late-Stage Uveal Melanoma Study as Investors Await Data
TipRanks · 5h ago
Revenue Slump Might Change The Case For Investing In IDEAYA Biosciences (IDYA)
Simply Wall St · 16h ago
IDEAYA Biosciences Is Maintained at Outperform by Mizuho
Dow Jones · 2d ago
IDEAYA Biosciences Price Target Cut to $39.00/Share From $44.00 by Mizuho
Dow Jones · 2d ago
Mizuho Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $39
Benzinga · 2d ago
Ideaya Biosciences price target lowered to $39 from $44 at Mizuho
TipRanks · 2d ago
Weekly Report: what happened at IDYA last week (1102-1106)?
Weekly Report · 3d ago
IDEAYA Biosciences (IDYA) Reports Earnings And Shelf Filing, Is The Stock Cheap?
Simply Wall St · 5d ago
IDEAYA Biosciences Is Maintained at Buy by Citigroup
Dow Jones · 6d ago
IDEAYA Biosciences Price Target Raised to $66.00/Share From $65.00 by Citigroup
Dow Jones · 6d ago
Citigroup Maintains Buy on IDEAYA Biosciences, Raises Price Target to $66
Benzinga · 6d ago
Leerink Partners Sticks to Their Hold Rating for IDEAYA Biosciences (IDYA)
TipRanks · 11/05 14:31
Citi Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)
TipRanks · 11/05 11:57
How Investors Are Reacting To IDEAYA Biosciences (IDYA) Earnings And Drug Trial Updates
Simply Wall St · 11/05 03:49
IDEAYA Biosciences Price Target Cut to $45.00/Share From $48.00 by RBC Capital
Dow Jones · 11/04 17:03
IDEAYA Biosciences Is Maintained at Outperform by RBC Capital
Dow Jones · 11/04 17:03
RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $45
Benzinga · 11/04 16:53
IDEAYA Biosciences Price Target Cut to $57.00/Share From $59.00 by Truist Securities
Dow Jones · 11/04 16:31
Truist Securities Reiterates Buy on IDEAYA Biosciences, Lowers Price Target to $57
Benzinga · 11/04 16:20
IDEAYA Biosciences Is Maintained at Buy by Guggenheim
Dow Jones · 11/04 15:23
More
Webull provides a variety of real-time IDYA stock news. You can receive the latest news about Ideaya Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About IDYA
IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.